



The Lilly TB Drug Discovery Initiative

Carole Heilman, Ph.D.

Dr. Carole Heilman is on the Board of Advisors for The Lilly TB Drug Discovery Initiative. She is the Director of the Division of Microbiology and Infectious Diseases (DMID), at the National Institute of Allergy and Infectious Diseases (NIAID), at the National Institutes of Health (NIH)/U.S. Department of Health and Human Services (DHHS).

As Director of DMID she has responsibility for scientific direction, oversight, and management of all extramural research programs on infectious diseases (except AIDS) within the NIH. In addition, since 2001, Dr. Heilman has played a critical role in launching and directing NIAID's extramural biodefense research program. Previously, Dr. Heilman served as Deputy Director of NIAID's Division of AIDS for three years.

After completing her post-doctoral work, Dr. Heilman worked at the National Cancer Institute as a senior staff fellow in molecular oncology. She moved into health science administration in 1986, focusing on respiratory pathogens, particularly vaccine development. She has received numerous awards for scientific management and leadership, including three DHHS Secretary's Awards for Distinguished Service for her contributions to developing pertussis, biodefense and AIDS vaccines.

Dr. Heilman has a Ph.D. in microbiology from Rutgers University. She did her post-doctoral work in molecular virology at the National Cancer Institute.